-+ 0.00%
-+ 0.00%
-+ 0.00%

Metavia Announces Preclinical Data From Head-To-Head Study Comparing Novel GLP-1 DA-1726 With Retatrutide; Sees Statistically Significant Increase In Liver And Circulating FGF21 Expression; Plans Phase 2 Study In MetALD And ALD H2 2027

Benzinga·11/16/2026 13:35:23
Listen to the news

MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive preclinical data from a head-to-head study comparing DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist, with retatrutide, a triple GLP-1R/GIPR/GCGR agonist. The findings, presented on November 14, 2026, at ObesityWeek® 2026 in Washington, D.C., demonstrated that DA-1726 increased hepatic fibroblast growth factor 21 (Fgf21) gene expression and liver FGF21 protein levels, along with enhanced expression of genes associated with thermogenesis and energy expenditure. DA-1726 also demonstrated greater glucose lowering and achieved weight loss comparable to retatrutide with less suppression of food intake.

The study compared DA-1726 to retatrutide in diet-induced obese (DIO) mice, assessing body weight, food intake, body composition, plasma metabolic parameters and thermogenesis-related gene expression. Animals received twice-weekly subcutaneous injections of DA-1726 at 300 or 500 nmol/kg or retatrutide at 100 or 200 nmol/kg for approximately three weeks. The higher doses were selected based on pharmacokinetic exposure estimates intended to approximate clinical exposures at 48 mg for DA-1726 and 12 mg for retatrutide.

DA-1726 demonstrated a statistically significant increase in hepatic expression of Fgf21 (p<0.05), showing both increased liver FGF21 protein and circulating FGF21 (p<0.001) at the higher dose. DA-1726 also induced greater expression of genes associated with brown adipose tissue thermogenesis and white adipose tissue browning compared with retatrutide. At the higher dose, expression of thermogenesis-related genes, including Ucp1, Ppargc1a and Fgf21, was increased in brown and inguinal white adipose tissue, with several markers demonstrating significantly greater expression than observed with high-dose retatrutide. These findings suggest that glucagon receptor-associated metabolic pathways, including those involving FGF21 and thermogenesis, may contribute to DA-1726's weight-loss effects.

DA-1726 also demonstrated greater glucose lowering compared with retatrutide, along with favorable effects on lipid metabolism. Plasma glucose levels decreased by 43.0% and 39.2% for DA-1726, versus reductions of 21.5% and 32.5% for retatrutide, at the low and high doses for each compound, respectively. Both showed improvements in plasma lipid parameters, with DA-1726 reducing total cholesterol by 70.9% and 69.3%, compared with 60.9% and 69.0% for retatrutide, and LDL cholesterol by 89.9% and 88.4%, compared with 82.8% and 88.1% for retatrutide, respectively. Comparable or numerically greater improvements in glucose and lipid parameters were consistently observed with DA-1726.

In addition, DA-1726 achieved weight loss similar to retatrutide despite less suppression of food intake. After adjustment relative to DIO controls, DA-1726 achieved body weight reductions of 34.2% and 41.7% compared with reductions of 33.7% and 43.6% for retatrutide, at the low and high doses for each compound, respectively. However, DA-1726 reduced food intake by 19.6% and 31.2%, compared with 36.7% and 41.4% for retatrutide, respectively. Both treatments also demonstrated comparable effects on body composition, including substantial reductions in fat mass. These findings suggest a potentially greater contribution of GCGR-associated energy expenditure to weight loss with DA-1726 than with retatrutide.

Taken together, these findings highlight DA-1726's differentiated metabolic profile, demonstrating weight loss comparable to retatrutide with less suppression of food intake, along with increased hepatic Fgf21 expression and protein levels and greater expression of genes associated with thermogenesis. The results suggest that GCGR-associated energy expenditure may play a greater role in DA-1726's weight-loss effects, providing additional preclinical support for its potential in liver-related cardiometabolic diseases.

Presentation Details:

Title: DA-1726 Demonstrates Comparable Weight Loss and Distinct Metabolic Profile Compared With Retatrutide
Session: Gut Peptides, Appetite Signaling & Novel Therapeutics
Presenting Author: Il Hoon Jeong, MS, Research Scientist, Dong-A ST Research Center 
Poster Number: Poster-229
A copy of the poster is available on the Posters section of the MetaVia website.